Patient Monitoring & Vital Signs in Florida

BeamMed Inc. is a US-based manufacturer and distributor of portable bone density scanning equipment for clinical and preventive care settings. The company specializes in quantitative ultrasound (QUS) bone densitometry, primarily through its flagship Sunlight MiniOmni product line—ultra-portable, handheld bone sonometers that weigh less than 2 lbs and deliver results in under one minute. The MiniOmni is designed for non-invasive, radiation-free bone mineral density assessment and is positioned to address HEDIS OMW (Osteoporosis Management in Women) quality measures and OMW-with-fracture gaps in Medicare Advantage and commercial health plans. The device supports USB connectivity to PC/laptop for reporting and EMR integration. BeamMed markets rental and purchase options to primary care practices, community health screening organizations, nursing homes, urgent care centers, and Medicare Advantage insurers. The company serves a broad range of high-profile health systems and payers (Kaiser Permanente, UnitedHealthcare, Humana, Optum, Blue Cross, Geisinger, Highmark, Elevance, and others) with documented success in improving HEDIS compliance and patient access to bone health screening. Products are described as portable, user-friendly, non-invasive, and cost-effective compared to traditional DEXA scanning. No specific FDA 510(k) numbers, ISO certifications, or CE marks are mentioned in the fetched content.

Healthcare MIT Services (HMS) is a medical technology company delivering AI-powered diagnostic imaging, intelligent patient monitoring, and connected care solutions. The company manufactures and distributes portable imaging systems, including low-dose fluoro-radiography and tabletop X-ray equipment designed for point-of-care, remote, and field deployment. Key product lines include contactless fall management and bedside monitoring systems utilizing AI-driven analysis without cameras or wearables; AI-enabled respiratory monitoring with noise-filtering capabilities; and clinical chemistry analyzers capable of running 16 tests in under 5 minutes with minimal blood samples (<90μL), ideal for remote and point-of-care settings. HMS also offers intelligent healthcare software solutions spanning smart ward and mobile nursing platforms, telehealth and remote care systems, and smart operating room integration. Medical supplies include certified PPE, mobile carts, and ready-to-deploy clinical kits. The company holds certifications including ISO 9001, ISO 13485, FDA clearance, EN 60601-1 medical device standard compliance, GMP, FCC, CUL, and CSA. HMS markets to hospitals, clinics, long-term care facilities, and field medical teams globally, with demonstrated presence at major medical conferences (HIMSS, RSNA, DMEA, AHCA/NCAL). The company emphasizes AI integration, radiation reduction, mobility, and safety across its product portfolio.

Ametris (formerly ActiGraph) is a digital health technology (DHT) company specializing in wearable medical devices and remote monitoring platforms for clinical research and drug development. The company provides FDA-cleared, medical-grade wearable devices paired with a scalable remote monitoring platform to capture objective, real-world patient data across multiple clinical domains. Ametris delivers an integrated, end-to-end solution combining hardware, cloud-based software, proprietary algorithms, and comprehensive operational and scientific support services. Core measurement capabilities include physical activity, gait and mobility analysis, sleep behavior monitoring, vital signs tracking, and cardinal symptom assessment. The platform is purpose-built to support all phases of the clinical trial lifecycle—from study design and site training to data collection, processing, archiving, and real-time monitoring. Ametris has established expertise in neuromuscular disorders, oncology, neuroscience, sleep medicine, and metabolic diseases. The company serves pharmaceutical sponsors, biotechnology firms, clinical research organizations (CROs), academic institutions, and hospital research networks across 150+ countries. With over 20 years of remote data capture expertise, 30,000+ peer-reviewed scientific publications supporting its technologies, and operational involvement in 285+ industry-sponsored clinical trials, Ametris positions itself as a scientific partner rather than a technology vendor alone. Services include endpoint design consultation, algorithm validation, regulatory strategy support, and DHT data interpretation. The company maintains headquarters in Pensacola, Florida, and operates a global support infrastructure with 24-hour critical support availability.

MESM LLC is now part of Resonant Clinical Solutions, a company specializing in equipment solutions and logistics support for clinical trials. The company provides end-to-end services encompassing sourcing, delivery, calibration, and equipment removal. MESM's core competency is infusion pump configuration and management, with technical expertise in ensuring seamless pump operation and patient safety throughout clinical studies. Beyond infusion systems, MESM supplies a broad range of clinical trial equipment including monitoring systems, refrigeration units, and diagnostic devices. The company delivers comprehensive clinical trial logistics support, including equipment procurement, management of ancillary supplies, and global distribution capabilities. MESM serves clinical research organizations (CROs), pharmaceutical sponsors, and contract research organizations (CROs) requiring reliable, calibrated medical equipment for multi-site and international trials. The organization emphasizes technical support, regulatory compliance, and preventing disruptions to trial operations. While specific regulatory certifications are not detailed in the available content, the nature of their work with clinical trials implies adherence to FDA and ICH-GCP standards.

SCHILLER Americas is a cardiopulmonary diagnostic device manufacturer and solutions provider with 50 years of innovation in medical diagnostics. The company specializes in electrocardiography (EKG), lung function testing, patient monitoring systems, and diagnostic station equipment. Their product portfolio includes EKG devices, the DS-20 Diagnostic Station, lung function testing systems (including the TREMOFLO), and multiparameter patient monitoring solutions. SCHILLER serves multiple market segments: general practice clinics, hospitals, specialized lung function laboratories, and government distributors. The company emphasizes integration of device hardware, clinical software, and ergonomic user interface design under their "Art of Diagnostics" philosophy. They offer service solutions, equipment trials (SCHILLER Trial Program), and ADA-compliant device options to support accessible patient care. Based in Doral, Florida, SCHILLER Americas operates as the North American division of the SCHILLER Group, a globally recognized medical device manufacturer. Their solutions are deployed across primary care, acute care, pulmonary specialty, and occupational health settings.

UpRight Science develops FDA-cleared balance assessment and fall-risk detection technology for clinical and research use. The company's core offering is a medical-grade, AI-driven platform that quantifies balance and gait dynamics to identify fall risks, neurological decline, and medication side effects. Their technology integrates machine learning algorithms trained on biomechanical datasets to provide clinicians and researchers with actionable insights for patient stratification and early intervention. The platform is validated in clinical trials and marketed as addressing balance as "the sixth vital sign"—positioning fall prevention as a critical health metric alongside traditional vital signs. UpRight Science targets healthcare providers, physical therapy clinics, geriatric care facilities, and research institutions. The technology combines motion analysis with predictive analytics to detect deviations linked to neurodegenerative diseases and other conditions affecting balance and gait. The company emphasizes evidence-based development leveraging decades of balance science research. Their go-to-market approach includes direct sales to clinical and research institutions via demonstrations and proof-of-concept studies.

PixCell Medical manufactures HemoScreen, a portable point-of-care (POC) complete blood count (CBC) analyzer designed to perform complex hematological testing in non-laboratory settings. The device delivers results in approximately 5 minutes and includes a 5-part differential count with clinical accuracy comparable to centralized laboratory instruments. The technology employs microfluidics, Lab-On-A-Cartridge design, and viscoelastic focusing—a proprietary physical phenomenon that aligns blood cells into a monolayer for optical analysis. HemoScreen accepts both venous and capillary (finger-stick) samples, enabling deployment in emergency departments, urgent care clinics, oncology practices, mental health facilities, primary care centers, and homecare settings. The company markets to healthcare practitioners and institutions seeking rapid turnaround for critical hematological decision-making. Testimonials from NHS trusts, university medical centers, and international healthcare systems indicate clinical adoption in the UK, Sweden, Denmark, and US. The device has received FDA clearance and is recognized by clinical organizations including AACC for disruptive technology. Manufacturing and service capabilities support both institutional and point-of-care deployment models.